ibrutinib to to be made available via cancer drugs fund after two trials .
trials , in 28 british hospitals , showed it to be extremely effective in treating mantle cell lymphoma and chronic lymphocytic leukaemia .
for now , ibrutinib -lrb- which costs up to # 74,000 a year -rrb- will be prescribed only to patients whose disease does n't respond to chemotherapy .